GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » Price-to-Tangible-Book

Protagonist Therapeutics (Protagonist Therapeutics) Price-to-Tangible-Book : 2.95 (As of May. 12, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics Price-to-Tangible-Book?

As of today (2024-05-12), Protagonist Therapeutics's share price is $28.23. Protagonist Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $9.56. Hence, Protagonist Therapeutics's Price to Tangible Book Ratio of today is 2.95.

The historical rank and industry rank for Protagonist Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

PTGX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.32   Med: 3.18   Max: 5.97
Current: 2.95

During the past 10 years, Protagonist Therapeutics's highest Price to Tangible Book Ratio was 5.97. The lowest was 1.32. And the median was 3.18.

PTGX's Price-to-Tangible-Book is ranked worse than
52.99% of 1221 companies
in the Biotechnology industry
Industry Median: 2.7 vs PTGX: 2.95

A closely related ratio is called PB Ratio. As of today, Protagonist Therapeutics's share price is $28.23. Protagonist Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $9.56. Hence, Protagonist Therapeutics's P/B Ratio of today is 2.95.


Protagonist Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Protagonist Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagonist Therapeutics Price-to-Tangible-Book Chart

Protagonist Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.40 3.15 5.45 2.50 3.93

Protagonist Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.47 5.40 3.18 3.93 3.02

Competitive Comparison of Protagonist Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Protagonist Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagonist Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's Price-to-Tangible-Book falls into.



Protagonist Therapeutics Price-to-Tangible-Book Calculation

Protagonist Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=28.23/9.564
=2.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Protagonist Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagonist Therapeutics (Protagonist Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Executives
Suneel Gupta officer: Chief Development Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Patel Dinesh V Ph D director, officer: President and CEO C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Bryan Giraudo director 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Harold E Selick director
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd director 3185 LAURELVIEW COURT, FREMONT CA 94538
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Asif Ali officer: Chief Financial Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Donald A. Kalkofen officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu officer: Chief Scientific Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame officer: Chief Medical Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035